LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

LLY

951.48

-2.19%↓

JNJ

221.7

-0.2%↓

ABBV

201.07

-0.69%↓

UNH

378.66

+2.77%↑

AZN

182.8

+0.21%↑

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Open

BrancheGesundheitswesen

0.33 -2.94

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.32

Max

0.34

Schlüsselkennzahlen
By Trading Economics
Einkommen	983K -47M
Verkäufe	505K 14M
Gewinnspanne	-342.329
Angestellte	161
EBITDA	-346K -46M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+1194.12% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-23M 82M
Vorheriger Eröffnungskurs	3.27
Vorheriger Schlusskurs	0.33

Nachrichtenstimmung

By Acuity

79%

21%

327 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.06 / 1.23 Unterstützung & Widerstand

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Mai 2026, 23:58 UTC

Ergebnisse

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7. Mai 2026, 22:57 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7. Mai 2026, 23:52 UTC

Ergebnisse

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7. Mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7. Mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7. Mai 2026, 23:11 UTC

Ergebnisse

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7. Mai 2026, 23:06 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7. Mai 2026, 23:05 UTC

Ergebnisse

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7. Mai 2026, 23:04 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7. Mai 2026, 23:03 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7. Mai 2026, 23:02 UTC

Ergebnisse

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7. Mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7. Mai 2026, 22:42 UTC

Ergebnisse

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7. Mai 2026, 22:33 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7. Mai 2026, 22:32 UTC

Ergebnisse

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7. Mai 2026, 22:31 UTC

Ergebnisse

Macquarie: 68% of FY Income From International >MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7. Mai 2026, 22:30 UTC

Ergebnisse

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7. Mai 2026, 22:29 UTC

Ergebnisse

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7. Mai 2026, 22:28 UTC

Ergebnisse

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7. Mai 2026, 22:27 UTC

Ergebnisse

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7. Mai 2026, 22:26 UTC

Ergebnisse

Macquarie to End Share Buyback Extended in November>MQG.AU

7. Mai 2026, 22:25 UTC

Ergebnisse

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

1194.12% Vorteil

12-Monats-Prognose

Durchschnitt 4.4 USD 1194.12%

Hoch 15 USD

Tief 0.3 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

327 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.